Innovative
Therapeutics for
Better Health

Because Life
Shouldn't Have to
Wait for Migraines

Our Lead Product Candidate

STS101

Dihydroergotamine (DHE) Nasal Powder

Learn More

Clinical Trials

SUMMIT™ Trial

Enrollment Complete

Learn More

Clinical Trials

ASCEND™ Trial

Ongoing

Learn More

Press Releases

May 18, 2023

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

Read More

Apr 21, 2023

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

Read More